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A randomized, double-blind, placebo-controlled study was conducted to evaluate the eﬃcacy of OciBest, an extract of Ocimum
tenuiﬂorum Linn. in symptomatic control of general stress. The participants received either placebo (n = 79) or OciBest (n = 71;
1200mg of actives per day) for sixweeks. The severity of stress-relatedsymptoms was self-evaluated by patients at weeks 0,2, 4and
6 of the trial period using a symptom rating scale. After six weeks of intervention, scores of symptoms such as forgetfulness, sexual
problems of recent origin, frequent feeling of exhaustion, and frequent sleep problems of recent origin decreased signiﬁcantly
(P ≤ 0.05) in OciBest group as compared with placebo group. Also, the total symptom scores of OciBest group revealed signiﬁcant
reduction (P ≤ 0.05) as compared to placebo group. The overall improvement in OciBest group was found to be 1.6 times or 39%
more in the control of general stress symptoms with respect to placebo. No adverse events were reported during the study. The
ﬁndings revealed that OciBest was found to be eﬀective and well tolerated by all the patients over the six weeks of study period.
1.Introduction
In modern society, stress is a common problem faced by
everyone in day-to-day life from diﬀerent sources like job,
family problems, pollution, noise etc. Stress is deﬁned as
psychological, physiological, and behavioural response by
individuals when they perceive a lack of equilibrium between
the demands placed upon them and their ability to meet
those demands [1]. The level of stress depends on the
threshold of each individual. Over a period of time the
response to stress aggravates and leads to ill-health [1, 2].
The common symptoms of stress include fatigue, tense-
ness, irritability, apathy, sleeping disorders, emotional insta-
bility, thoughts, and concentration problems [3]. Present
generation people are more ravaged by the consequences of
stress than at any time in past, and ﬁnancial expenses in
terms of long-term sick leave due to stress-related mental
disorders are extensive [4]. Nearly 75% to 90% patient visits
to primary care physicians are related to stress problems.
In USA, health and eﬃciency costs of worker stress were
reported to be between $50 and $150 billion per annum, and
irrepressible stress revealed to be high risk factor for cancer
and heart disease than either cigarette smoking or intake
of high-cholesterol diets [5–8]. Psychological problems due
to enormous workloads among employees have increased
at a faster rate in many countries. In England, around 40
million workdays per year have been lost owing to mental
and emotional problems [9].2 Evidence-Based Complementary and Alternative Medicine
Management of any unusual stress has acquired signiﬁ-
cant implications in daily life. Whereas complete avoidance
of stress is unlikely, any intervention that facilitates elevation
of threshold level can be beneﬁcial. In order to curtail the
economic losses towards the stress-related disorders and to
improve the quality of life, traditional therapies seem to be
promisingalternatives.Indiansystemoftraditionalmedicine
describes remedies based on herbal supplementation, min-
erals, and other therapeutic procedures for enhancing phys-
ical and mental performance to evade the stress levels
[10–13].
Ocimum tenuiﬂorum Linn. (synonym: Ocimum sanc-
tum), generally known as Tulsi or Holy Basil, belongs to fam-
ily lamiaceae. In Ayurveda, O. tenuiﬂorum has been used
for adaptogenic/antistress activity [14]. It has been widely
reported to possess antipyretic [15], antiasthmatic [16],
antioxidant [17, 18], analgesic [19], and anti-inﬂammatory
properties [20]. O. sanctum prevented reduction in the levels
ofbraincatecholamineandmonoamineoxidaseandincrease
in dopamine and 5-hydroxytryptamine in rats exposed to
swimming and gravitational stress [21].
Despite the availability of extensive preclinical evidences
on antistress activity of O. tenuiﬂorum, authenticated clinical
data are found to be lacking. A study by Bhattacharyya
et al. that revealed the promising eﬀects of O. sanctum
(500mg/capsule, twice daily after meal) for a period of two
months in the management of patients suﬀering from gen-
eralized anxiety disorder (GAD) remains the only pertinent
clinical evidence published on the medicinal herb till date
[22].
2.ParticipantsandMethods
2.1. Participants. The present study was carried out at two
diﬀerent centers in Lucknow, India between April 2008
and September 2009. Patients were recruited according to
the inclusion criteria if they (i) were aged between 18–
65 years, (ii) had given written consent, (iii) agreed to
come for followup at week 2, 4, and 6 irrespective of any
relief or appearance of side eﬀects, and (iv) were suﬀering
from at least any three of the symptoms of stress shown
(Table 1). Patients were excluded if they (i) were unable to
give voluntary consent, (ii) had history of signiﬁcant cardiac,
hepatic, renal, brain, or blood-allergic diseases, (iii) had
physical disabilities, (iv) were taking allopathic or herbal
medicines or participating in any other clinical trial, or (v)
were pregnant/breast feeding.
One sixty-seven patients were screened for selection
criteria, of which 158 were selected for the study after
obtaining the written consent from each individual by the
investigators. The study was approved by Institutional Ethics
Committee.
2.2. Study Intervention. OciBest, an extract of whole plant of
O. tenuiﬂorum Linn. was developed by M/s Natural Reme-
dies Pvt. Ltd., Bangalore, India. The extract was ensured
to comply with phytochemical speciﬁcations, namely,
Ociglycoside-I(Hydroxychavicolglucoside/4-allyl-1-O-β-D-
glucopyronosyl-2-hydroxybenzene; >0.1%w/w), rosmarinic
Table 1: Symptoms of stress.
(i) Headache
(ii) Palpitation at rest
(iii) Abnormal perception of hearing
(iv) Blurring of vision
(v) Forgetfulness
(vi) Sexual problems of recent origin
(vii) Frequent GI symptoms, lack of appetite, or dislike of even
favourite food
(viii) Abnormal movements of upper limb, tics, tremors,
scratching
(ix) Abnormal sensory perceptions particularly of lower limbs
and face
(x) Quarrelsome behaviour with later realizing of mistake
(xi) Frequent feeling of exhaustion or overworked
(xii) Frequent sleep problems of recent origin
(xiii) Avoidance of even familiar people
(xiv) Missing appointments for other things less important
acid (>0.2%w/w), and triterpene acids (>2.5%w/w). The
composition adhered to the international quality require-
ments which included analysis of solvent residues, heavy
metals, pesticide residues, and microbial contamination. The
placebo capsules contained microcrystalline cellulose. Each
OciBest capsule contained 400mg of actives. The placebo
and OciBest were ﬁlled in “0” size blue-coloured, hard-
gelatin capsules that could not be distinguished from each
other. Each container was packed with 42 capsules and
labeled with code number.
2.3. Randomization and Blinding. The patients enrolled
for clinical trial were allotted to placebo and OciBest
groups. To identify the patient code, a list of unique
integer random numbers were obtained after generating the
random allocation number using a computer-aided random
series programme. According to the random allocation
sequence, the distinct random numbers were mentioned in
the respective containers (placebo or OciBest). The packed
containers were dispatched from Natural Remedies Pvt. Ltd.,
Bangalore, India to the study centers. The entire process was
accomplished in concealed manner. As per enrollment and
random allocation sequence the pharmacist dispensed the
study intervention and was responsible for the same. The
study investigators, pharmacist, and the participants were all
blinded during the trial period.
2.4. Study Protocol. The study was performed in a random-
ized, double-blind, placebo-controlled manner. One ﬁfty-
eight patients were selected for the study and randomly
assigned to placebo and OciBest group. Each patient was
handed over one container and advised to take one capsule
after breakfast and two capsules after dinner (total 1200mg
of actives per day) for 2 weeks. After 2 weeks, the patient was
asked to report for followup and symptoms reassessment.
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compliance. Fresh container of 42 capsules was provided
after recording the compliance. Similar process was repeated
when the patient reported for followup during week 4.
2.5. Outcome Measures. The symptom scores of patients
(Table 1) were assessed on week 0 and thereafter followup
on weeks 2, 4, and 6 of the study period. On each occasion,
the patients were asked to grade themselves for all individual
symptoms based on the symptom rating scale [23].
2.6. Sample Size. The required sample size for diﬀerence
between two means, that is, for a two sample t-test was
estimated according to Dell et al. [24] .T h es a m p l es i z ew a s
calculated with a power of 90% and value of alpha = 0.05.
Thus, minimum 65 subjects were required for each group
and total 130 subjects for the whole study. Due to self-
limiting condition in stress and as drop outs are common
in clinical trial [25], additional subjects were added in each
group.
2.7. Statistical Analysis. One hundred and ﬁfty participants
were considered for statistical analysis. The baseline demo-
graphic characteristics of two groups were compared by
independentStudent’st-test.Thescoreofeachsymptomwas
analyzed using RMANOVA. The statistical signiﬁcance was
set at P ≤ 0.05. The statistical applications were performed
using SPSS (version 13) and STATISTICA (version 7.0)
softwares. The eﬀect of two groups on each symptom and
total symptoms scores were calculated as the reduction in
symptom severity scores from baseline (week 0) to ﬁnal
assessment (week 6). The eﬀect size of individual and total
symptomswascalculatedasthediﬀerencebetweentheeﬀects
of placebo and OciBest. The overall eﬀect size (%) between
two groups was calculated as
Overall eﬀect size (%) =

Ocibest −Placebo
Ocibest

×100.
(1)
3. Results
3.1. Demographic Data. Out of 167 subjects assessed for
eligibility, a total of 158 patients (placebo = 82; 45 males and
37 females and OciBest = 76; 44 males and 32 females) who
fulﬁlled the selection criteria and willing to give informed
consent were enrolled in the study and randomized to
either placebo or OciBest groups. On comparison, the
demographiccharacteristicsofallpatientsatbaselinedidnot
diﬀer signiﬁcantly in any of the parameters (Table 2).
3.2.SymptomaticAssessmentofEﬃcacy. Thesymptom scores
of patients of placebo and OciBest groups were summarized
in Table 3. There was no signiﬁcant diﬀerence between the
individual symptom scores of participants of OciBest group
as comparedto placebo group on week 0. In both the groups,
mean scores of all individual symptoms showed a decreasing
t r e n df r o mw e e k0t ow e e k6e x c e p tf o rf e ws y m p t o m si n
placebo which either remained constant (Avoidance of even
Table 2: Summary of demographic information.
Characteristics Placebo OciBest t-value
Male/female 45/37 44/32 —
Age (years) 47.56 ±1.11 48.53 ±1.16 0.60ns
Weight (kg) 64.77 ±1.19 64.30 ±1.16 0.28ns
Height (cm) 161.07 ±0.92 163.13 ±1.20 1.37ns
Heart rate/min 79.20 ±0.77 81.58 ±1.11 1.79ns
BP diastolic (mmHg) 134.88 ±1.87 133.28 ±1.85 0.61ns
BP systolic (mmHg) 83.99 ±0.85 82.58 ±0.87 1.16ns
Values are expressed as mean ± SEM; Placebo n = 82; OciBest n = 76
Ns—non signiﬁcant.
familiar people, and missing appointments) or got aggra-
vated (Blurring of vision, abnormal sensory perceptions, and
frequent sleep problems) from week 4 to week 6.
Mean scores of all symptoms in OciBest group decreased
signiﬁcantly (P ≤ 0.05) from week 0 to weeks 2, 4, and
6 except for sexual problems of recent origin at week 2
while placebo group showed either nonsigniﬁcant decrease
(abnormal perception of hearing, sexual problems of recent
origin, abnormal sensory perceptions, avoidance of even
familiar people, and missing appointments) or signiﬁcant
decrease from week 0 to weeks 2, 4, and 6 in few symptoms
(headache, palpitation at rest, frequent gastrointestinal (GI)
symptoms,frequentfeelingofexhaustion,andfrequentsleep
problems) and week 0 to weeks 4 and 6 in other symp-
toms (Blurring of vision, forgetfulness, and quarrelsome
behaviour). Signiﬁcant decrease was noticed in abnormal
movements only from week 0 to week 6 in placebo-treated
group.
Among all parameters, mean scores of headache, pal-
pitation at rest, frequent GI symptoms, and frequent sleep
problems decreased signiﬁcantly (P ≤ 0.05) from week
2 to weeks 4 and 6, and mean scores of forgetfulness,
sexual problems of recent origin, quarrelsome behaviour
and frequent feeling of exhaustion decreased signiﬁcantly
(P ≤ 0.05) from week 2 to week 6 in OciBest group. But in
placebogroup, mostofthesymptoms showednonsigniﬁcant
decrease except in few symptoms signiﬁcant decrease (P ≤
0.05) was noticed from week 2 to weeks 4 and 6 (frequent GI
symptoms, frequent feeling of exhaustion and frequent sleep
problems) and week 2 to week 6 (headache and quarrelsome
behaviour).
On comparison, mean scores of forgetfulness, sexual
problems of recent origin, quarrelsome behaviour, frequent
feeling of exhaustion and frequent sleep problems decreased
signiﬁcantly (P ≤ 0.0 5 )f r o mw e e k4t ow e e k6i nO c i B e s t
group while in placebo group, all symptoms showed non-
signiﬁcant decrease from week 4 to week 6 except for
quarrelsome behaviour.
Comparingmeanbetweenbothgroups,theeﬀectofboth
the treatments on all symptoms at week 2 and 4 was found
to be the same while at week 6, symptoms of forgetfulness,
sexual problems of recent origin, frequent feeling of exhaus-
tion, and frequent sleep problems improved signiﬁcantly
(P ≤ 0.05) in OciBest-treated group as compared to placebo
group.4 Evidence-Based Complementary and Alternative Medicine
A l l o c a t e dt oi n t e r v e n t i o n( n = 76)
Received allocated intervention
(n = 76)
Did not receive allocated intervention
(n = 0)
Give reasons -
Assessed for eligibility (n = 167)
Analysis
Allocation
Enrollment (n = 158)
Is it randomized: yes
OciBest Placebo
Followup
Give reasons-unknown
Discontinued intervention
(n = 0)
Give reasons -
Lost to followup (n = 05)
Received allocated intervention
(n = 82)
Did not receive allocated intervention
(n = 0)
Give reasons -
Allocated to intervention (n = 82)
Give reasons-unknown
Discontinued intervention
(n = 0)
Lost to followup (n = 03)
Give reasons -
Analyzed (n = 79)
Excluded from analysis (n = 0)
Give reasons -
Analyzed (n = 71)
Excluded from analysis (n = 0)
Give reasons -
Figure 1: Disposition of patients.
Totalscoresofallsymptomsinboththegroupsdecreased
signiﬁcantly (P ≤ 0.05) at all consecutive week intervals as
compared to weeks 0, 2 and 4. At the end of the study, the
between groups analysis of total symptom scores of OciBest
revealed signiﬁcant reduction (P ≤ 0.05) as compared to
placebo. The eﬀect of OciBest over placebo on comparison
was considerable for all stress parameters. The overall eﬀect
size of OciBest was found to be 39% (1.6 times) higher than
placebo (Table 3).
3.3. Drop Outs. Out of 158 enrolled patients at baseline,
three patients in placebo and ﬁve patients in OciBest treated
group did not turn up for followup and were excluded from
data analysis. Thus symptom scores of 79 patients in placebo
and 71 in test group were analyzed statistically (Figure 1).
3.4. Adverse Eﬀects. None of the patients from both groups
(placebo and OciBest) reported any adverse eﬀects.
4. Discussion
Current pharmacological investigations focus on alleviating
symptoms of stress since physical strains and psychological
pressures have become integral and inevitable components
of present life situations. Recently, herbal extracts and sup-
plements have gained global recognition for stress-relieving
potentials[26–28],inadditiontopopularmedicinalusesand
widely accepted safety proﬁle [29–32].
The ﬁndings of a recent study proposed that people
suﬀering from uncontrolled stress experienced impairment
of short-term memory and other relevant functions in the
prefrontal cortex induced by protein kinase C [33]. In the
current study, supplementation with OciBest signiﬁcantly
decreased the intensity of forgetfulness to about one-third
observed in placebo group. Additionally, the eﬀect size was
found to be the maximum (0.70) which elucidated that the
participants of OciBest group were highly improved from
forgetfulness than from any other symptoms.Evidence-Based Complementary and Alternative Medicine 5
Table 3: Eﬀect of OciBest on symptom scores of stress.
Symptoms Groups Assessment period EﬀectX Eﬀect sizeY
Week 0 Week 2 Week 4 Week 6
Headache Placebo 1.34 ±0.17 0.96 ±0.14a 0.78 ±0.13a 0.58 ±0.12ab 0.76 ±0.16
OciBest 1.24 ±0.18 0.77 ±0.14a 0.51 ±0.11ab 0.31 ±0.09ab 0.93 ±0.15 0.17
Palpitation at rest Placebo 1.29 ±0.16 0.76 ±0.12a 0.66 ±0.11a 0.51 ±0.11a 0.78 ±0.15
OciBest 1.56 ±0.19 0.93 ±0.14a 0.59 ±0.12ab 0.46 ±0.11ab 1.10 ±0.17 0.31
Abnormal perception of hearing Placebo 0.25 ±0.09 0.20 ±0.08 0.18 ±0.06 0.14 ±0.06 0.11 ±0.05
OciBest 0.45 ±0.13 0.30 ±0.09a 0.27 ±0.09a 0.21 ±0.08a 0.24 ±0.08 0.13
Blurring of vision Placebo 0.51 ±0.13 0.37 ±0.10 0.28 ±0.08a 0.29 ±0.09a 0.22 ±0.07
OciBest 0.75 ±0.14 0.45 ±0.10a 0.31 ±0.09a 0.28 ±0.09a 0.46 ±0.11 0.25
Forgetfulness Placebo 1.25 ±0.17 1.10 ±0.16 0.99 ±0.15a 0.95 ±0.15a 0.30 ±0.08
OciBest 1.32 ±0.19 1.03 ±0.16a 0.87 ±0.14a 0.32 ±0.08abc∗
1.00 ±0.15 0.70
Sexual problems of recent origin Placebo 0.71 ±0.16 0.65 ±0.14 0.61 ±0.14 0.56 ±0.13 0.15 ±0.05
OciBest 0.85 ±0.17 0.75 ±0.16 0.54 ±0.12a 0.07 ±0.03abc∗
0.77 ±0.16 0.62
Frequent GI symptoms Placebo 1.61 ±0.18 1.11 ±0.14a 0.77 ±0.13ab 0.59 ±0.11ab 1.01 ±0.15
OciBest 1.63 ±0.20 1.07 ±0.15a 0.63 ±0.12ab 0.44 ±0.10ab 1.20 ±0.17 0.18
Abnormal movements Placebo 0.39 ±0.11 0.35 ±0.11 0.28 ±0.09 0.20 ±0.08a 0.19 ±0.08
OciBest 0.44 ±0.12 0.27 ±0.10a 0.23 ±0.09a 0.20 ±0.08a 0.24 ±0.08 0.05
Abnormal sensory perceptions Placebo 0.25 ±0.09 0.16 ±0.06 0.14 ±0.06 0.15 ±0.07 0.10 ±0.05
OciBest 0.48 ±0.13 0.32 ±0.11a 0.27 ±0.10a 0.25 ±0.10a 0.23 ±0.09 0.12
Quarrelsome behavior Placebo 1.06 ±0.17 0.96 ±0.16 0.82 ±0.15a 0.65 ±0.12abc 0.42 ±0.09
OciBest 0.90 ±0.19 0.70 ±0.15a 0.59 ±0.13a 0.34 ±0.09abc 0.56 ±0.13 0.15
Frequent feeling of exhaustion Placebo 2.00 ±0.17 1.53 ±0.14a 1.19 ±0.13ab 1.04 ±0.14ab 0.96 ±0.14
OciBest 1.72 ±0.19 1.13 ±0.15a 0.86 ±0.13a 0.37 ±0.08abc∗
1.35 ±0.17 0.39
Frequent sleep problems Placebo 1.49 ±0.17 1.14 ±0.14a 0.82 ±0.13ab 0.84 ±0.14ab 0.66 ±0.12
OciBest 1.30 ±0.19 0.89 ±0.15a 0.58 ±0.13ab 0.27 ±0.08abc∗
1.03 ±0.17 0.37
Avoidance of even familiar people Placebo 0.28 ±0.10 0.23 ±0.08 0.20 ±0.08 0.20 ±0.08 0.08 ±0.06
OciBest 0.38 ±0.12 0.21 ±0.09a 0.17 ±0.07a 0.10 ±0.05a 0.28 ±0.11 0.21
Missing appointments Placebo 0.14 ±0.07 0.13 ±0.06 0.05 ±0.03 0.05 ±0.03 0.09 ±0.05
OciBest 0.25 ±0.09 0.14 ±0.07a 0.11 ±0.06a 0.07 ±0.04a 0.18 ±0.07 0.09
Total Placebo 12.58 ±0.48 9.66 ±0.44a 7.77 ±0.46ab 6.75 ±0.45abc 5.84 ±0.54
OciBest 13.27 ±0.46 8.96 ±0.43a 6.52 ±0.45ab 3.69 ±0.37abc∗
9.58 ±0.52 3.74
Values are expressed as mean ± SEM; Placebo n = 79; OciBest n = 71.
aP ≤ 0.05 versus week 0; bP ≤ 0.05 versus week 2; cP ≤ 0.05 versus week 4.
∗P ≤ 0.05— placebo versus OciBest.
XDiﬀerence in mean scores between week 0 and week 6; YDi ﬀerence in mean scores between placebo and OciBest.
Sexual problems and stress are related in several ways.
Psychological causes that arise due to work-related stress
resultinsexualproblems.Excessivestresscanleadtoreduced
libido/sex drive in both sexes [34, 35]. Our ﬁndings showed
thatO.tenuiﬂorumextractremarkablyreducedthesymptom
scoresofsexualproblemsby87.5%incomparisontopatients
of placebo group.
In contrast to acute stress that accelerates neurotransmit-
ters and hormones from the nervous and endocrine systems
which in turn will enhance immune system functions,
chronic stress aggravates exhaustion, distress, and disease
[36, 37]. In the present investigation, OciBest administration
provided eﬀective relief from frequent feeling of fatigue.
Similarly, disturbances in regular sleeping habits are encoun-
tered with stressful life style. Also, daytime sleepiness has
been reported with prolonged stress exposures [38]. The
results of the present clinical trial exhibited that the herbal
intervention considerably reduced the intensity of symptom
from 0.84 ± 0.14 to 0.27 ± 0.08.
The overall eﬀects of extract of O. tenuiﬂorum in patients
with stress were found to be signiﬁcant as compared to
placebo which can be attributed to the inﬂuence of herbal
supplement on four major symptoms like forgetfulness, sex-
ual problems of recent origin, frequent feeling of exhaustion,
and frequent sleep problems. The probable mechanisms
of adaptogenic eﬀects, from previously established studies,
couldbeascribedtoneuroprotective[39],immunostimulant
[40], free radical scavenging [41], nonspeciﬁc resistance
inducing and plasma cortisol lowering [42]e ﬀects of O.
sanctum.6 Evidence-Based Complementary and Alternative Medicine
The major phytochemical principles of Holy Basil largely
contribute to its pharmacological actions. Saravanan and
Pugalendi in 2006 reported that the triterpenoid ursolic
acid at 20mg per kg per day for 30 days could be able to
amelioratetheoxidativestressinratheartinducedbychronic
ethanol intoxication by reversing the peroxidative damages
and concurrently enhancing the activities of antioxidant
enzymes [43]. Another triterpenoid—Oleanolic acid pro-
tectedmousemacrophagesagainstoxidativeandelectrophile
stress [39].
From the results of the present study, it is also evident
that the severity of other symptoms such as headache,
palpitation at rest, abnormal perception of hearing, blurring
of vision, frequent GI symptoms, abnormal sensory percep-
tions, quarrelsome behavior, and avoidance of familiar peo-
plelessenedtocertainextentduetodietarysupplementation.
Although the scores of symptoms like abnormal movements
ofupperlimb,tics,tremors,scratching,andmissingappoint-
ments did not improve after six weeks of intervention,
these symptoms are infrequently reported in stress patients.
The positive trends of the present investigation can be
corroborated with the research ﬁndings on O. tenuiﬂorum
for stress management [44]. The diﬀerent components of
stress response include enhancement of central nervous
systemprocessesandtheinteractionbetweenhypothalamus-
pituitary-adrenocortical (HPA) axis [45]. Bhattacharyya et
al. stated that, in human subjects, O. sanctum acts potentially
in the regulation of HPA axis in stress-related disorders
[22].
Ontheotherhand,analysisofstudyresultsalsoindicated
presence of placebo eﬀect to some extent which is commonly
anticipated as a regular incidence in several clinical trials
[26, 46]. However, the critical observations on self-evaluated
scores of study endpoints reinforce the fact that few symp-
toms in placebo group either remained constant (avoidance
of even familiar people and missing appointments) or got
aggravated (blurring of vision, abnormal sensory percep-
tions, and frequent sleep problems) from week 4 to week 6.
Pertinent to safety, OciBest administration was found to
be well tolerated in stress patients and no adverse events
were recorded during the clinical trial. Earlier research by
Bhattacharyya et al. in GAD patients also conﬁrmed the
overall safety of O. sanctum [22]. As mentioned previously,
the wide margin of safety reported in experimental animal
species tends to support the medicinal plant for human use
[11].
In conclusion, the study ﬁndings revealed that OciBest,
the whole plant extract of O. tenuiﬂorum,w a sf o u n dt ob e
1.6 times or 39% more eﬀective in the management of stress
symptoms in comparison to placebo group and the herbal
supplementation was well tolerated by all the patients over
the six weeks of study period.
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